Literature DB >> 12207866

A novel HPLC assay for pentamidine: comparative effects of creatinine and inulin on GFR estimation and pentamidine renal excretion in the isolated perfused rat kidney.

Nagaraju R Poola1, Dider Bhuiyan, Stephan Ortiz, Ishani A Savant, Madiha Sidhom, David R Taft, Harold Kirschenbaum, Michelle Kalis.   

Abstract

PURPOSE: 1. To develop and validate an analytical method for pentamidine (PTM) by reversed-phase HPLC. 2. To compare the effects of creatinine and inulin on PTM excretion in the isolated perfused rat kidney.
METHODS: The HPLC method utilized a base deactivated, 5 micro, C18 column and a mobile phase containing acetonitrile (24%) and 0.025 M monobasic phosphate buffer, pH 3.2 (76%). Mobile phase flow rate and UV detection wavelength were 1 mL/min and 270 nm, respectively. Sulfadiazine (SDZ) was used as the internal standard. The method was used to measure pentamidine in perfusate and urine samples generated from studies with the isolated perfused rat kidney (IPK) model. Perfusion experiments were conducted in the presence of two different GFR markers: creatinine and inulin (PTM dose 800 micro g). Both creatinine and inulin were assayed using colorimetric methods.
RESULTS: The HPLC assay is rapid, sensitive and reproducible. The method was validated over two standard concentration ranges: 0.1 to 1 micro g/mL, and 1 to 10 micro g/mL. In control (drug-naïve) IPK perfusions, creatinine clearance was approximately 15% greater than inulin clearance (0.80+/- 0.21 mL/min vs. 0.69+/-0.17 mL/min, p > 0.05). In the presence of PTM, however, creatinine clearance was reduced to 0.56+/-0.27 (p < 0.05 compared to control). Inulin clearance was not altered by PTM administration (0.76+/-0.26 mL/min). Cumulative urinary excretion of PTM (% dose) was 3.0+/-0.47% and 9.6+/-4.2% in the presence of creatinine and inulin, respectively. PTM clearance was significantly reduced (0.06+/-0.01 mL/min vs. 0.13+/-0.01 mL/min, p < 0.05) and % kidney accumulation significantly enhanced (66+/-4.7% vs. 37+/-9.7%, p < 0.05) by creatinine.
CONCLUSIONS: Creatinine overestimated GFR in the IPK. The altered renal excretion of PTM by creatinine is consistent with inhibition of PTM tubular secretion. Because of increased kidney accumulation, detrimental effects of PTM on renal function were observed. Based on these findings, creatinine should be used cautiously as an indicator of GFR in IPK experimentation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12207866

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  6 in total

1.  Renal excretion of apricitabine in rats: ex vivo and in vivo studies.

Authors:  Mariana Babayeva; Susan Cox; Michael P White; David R Taft
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-04-06       Impact factor: 2.441

2.  Development of a rat model of D-galactosamine/lipopolysaccharide induced hepatorenal syndrome.

Authors:  Jing-Bo Wang; Hai-Tao Wang; Lu-Ping Li; Ying-Chun Yan; Wei Wang; Jing-Yang Liu; Yi-Tong Zhao; Wei-Shu Gao; Ming-Xiang Zhang
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

3.  Role of TRPV1 channels in renal haemodynamics and function in Dahl salt-sensitive hypertensive rats.

Authors:  Jianping Li; Donna H Wang
Journal:  Exp Physiol       Date:  2008-04-10       Impact factor: 2.969

4.  Increased GFR and renal excretory function by activation of TRPV1 in the isolated perfused kidney.

Authors:  Jianping Li; Donna H Wang
Journal:  Pharmacol Res       Date:  2008-02-02       Impact factor: 7.658

5.  Using an isolated rat kidney model to identify kidney origin proteins in urine.

Authors:  Lulu Jia; Xundou Li; Chen Shao; Lilong Wei; Menglin Li; Zhengguang Guo; Zhihong Liu; Youhe Gao
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

6.  Development and Validation of an HPLC Method for Determination of Antidiabetic Drug Alogliptin Benzoate in Bulk and Tablets.

Authors:  Hani Naseef; Ramzi Moqadi; Moammal Qurt
Journal:  J Anal Methods Chem       Date:  2018-09-24       Impact factor: 2.193

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.